Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
25 Mayo 2022 - 7:00AM
Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage
macrophage reprogramming immunotherapy company targeting diseased
macrophages in patients with sepsis and solid tumors, today
announced that the Israel Innovation Authority (IIA) selected
Enlivex’s ongoing sepsis clinical program to receive a
thirdnon-dilutive grant of approximately $1.2 million for 2022. To
date, Enlivex has received a total of approximately $7.8 million in
non-dilutive grants from the IIA for clinical trials and product
development, excluding this newly approved grant.
The IIA is an independent, publicly funded agency charged with
fostering the development of industrial research and development
within the State of Israel. It provides non-dilutive grants in the
form of reimbursement for actual expenses pre-approved by the IIA.
The grants become repayable only through royalties from future
sales of products developed with the support of the IIA, and the
repayment, if any, is limited to the original grant amount plus
interest.
Enlivex is currently recruiting patients to its Phase IIb trial
of AllocetraTM for the treatment of organ dysfunction associated
with sepsis.
ABOUT ALLOCETRA™
Enlivex is developing AllocetraTM as a universal, off-the-shelf
cell therapy designed to reprogram macrophages into their
homeostatic state. Diseases such as solid cancers, sepsis, and many
others reprogram macrophages out of their homeostatic state. These
non-homeostatic macrophages contribute significantly to the
severity of the respective diseases. By restoring macrophage
homeostasis, AllocetraTM has the potential to provide a novel
immunotherapeutic mechanism of action for life-threatening
clinical indications that are defined as “unmet medical needs”, as
a stand-alone therapy or in combination with leading therapeutic
agents.
ABOUT ENLIVEXEnlivex is a clinical stage
macrophage reprogramming immunotherapy company developing
Allocetra™, a universal, off-the-shelf cell therapy designed
to reprogram macrophages into their homeostatic state.
Resetting non-homeostatic macrophages into their homeostatic state
is critical for immune system rebalancing and resolution of
life-threatening conditions. For more information visit
https://enlivex.com/.
Safe Harbor Statement: This press release contains
forward-looking statements, which may be identified by words such
as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,”
“believes,” “should,” “would”, “could,” “intends,” “estimates,”
“suggests,” “has the potential to” and other words of similar
meaning, including statements regarding expected cash balances,
market opportunities for the results of current clinical studies
and preclinical experiments, the effectiveness of, and market
opportunities for, ALLOCETRATM programs. All such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that forward-looking statements
involve risks and uncertainties that may affect Enlivex’s business
and prospects, including the risks that Enlivex may not succeed in
generating any revenues or developing any commercial products; that
the products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would
support the approval or marketing of these products for the
indications being studied or for other indications; that ongoing
studies may not continue to show substantial or any activity; and
other risks and uncertainties that may cause results to differ
materially from those set forth in the forward-looking statements.
The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials
in animals. The results of early-stage trials may differ
significantly from the results of more developed, later-stage
trials. The development of any products using the
ALLOCETRATM product line could also be affected by a number of
other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors
described above, investors should consider the economic,
competitive, governmental, technological and other factors
discussed in Enlivex’s filings with the Securities and Exchange
Commission, including in the Company’s most recent Annual Report on
Form 20-F filed with the Securities and Exchange Commission.
The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements,
except as required under applicable law.
ENLIVEX CONTACT:
Shachar
Shlosberger, CFO
Enlivex
Therapeutics,
Ltd.
shachar@enlivexpharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024